ES2570184T3 - Compuestos para dirigir la administración de fármacos y potenciar la actividad de ARNip - Google Patents

Compuestos para dirigir la administración de fármacos y potenciar la actividad de ARNip

Info

Publication number
ES2570184T3
ES2570184T3 ES12728010T ES12728010T ES2570184T3 ES 2570184 T3 ES2570184 T3 ES 2570184T3 ES 12728010 T ES12728010 T ES 12728010T ES 12728010 T ES12728010 T ES 12728010T ES 2570184 T3 ES2570184 T3 ES 2570184T3
Authority
ES
Spain
Prior art keywords
group
sirna
drugs
administration
enhance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12728010T
Other languages
English (en)
Spanish (es)
Inventor
C Nagarajan Sridhar
Priya Karmali
Yoshiro Niitsu
Joseph E Payne
Zheng Hou
John A Gaudette
Victor Knopov
Richard P Witte
Mohammad Ahmadian
Loren A Perelman
Yasunobu Tanaka
Violetta Akopian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Application granted granted Critical
Publication of ES2570184T3 publication Critical patent/ES2570184T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/06—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton from hydroxy amines by reactions involving the etherification or esterification of hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES12728010T 2011-06-08 2012-06-08 Compuestos para dirigir la administración de fármacos y potenciar la actividad de ARNip Active ES2570184T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494710P 2011-06-08 2011-06-08
US201161494840P 2011-06-08 2011-06-08
PCT/US2012/041753 WO2012170952A2 (en) 2011-06-08 2012-06-08 Compounds for targeting drug delivery and enhancing sirna activity

Publications (1)

Publication Number Publication Date
ES2570184T3 true ES2570184T3 (es) 2016-05-17

Family

ID=46317540

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12728010T Active ES2570184T3 (es) 2011-06-08 2012-06-08 Compuestos para dirigir la administración de fármacos y potenciar la actividad de ARNip
ES15181729T Active ES2743540T3 (es) 2011-06-08 2012-06-08 Compuestos para dirigir la administración de fármacos y potenciar la actividad de ARNip

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15181729T Active ES2743540T3 (es) 2011-06-08 2012-06-08 Compuestos para dirigir la administración de fármacos y potenciar la actividad de ARNip

Country Status (20)

Country Link
EP (2) EP2998289B1 (enExample)
JP (3) JP5873553B2 (enExample)
KR (3) KR102038300B1 (enExample)
CN (3) CN103857654B (enExample)
AU (2) AU2012267467B8 (enExample)
CA (2) CA2837101C (enExample)
CY (2) CY1117433T1 (enExample)
DK (2) DK2718261T3 (enExample)
ES (2) ES2570184T3 (enExample)
HR (1) HRP20191463T8 (enExample)
HU (1) HUE045821T2 (enExample)
LT (1) LT2998289T (enExample)
PL (2) PL2998289T3 (enExample)
PT (1) PT2998289T (enExample)
RS (1) RS59380B1 (enExample)
RU (2) RU2632888C2 (enExample)
SI (1) SI2998289T1 (enExample)
SM (1) SMT201900523T1 (enExample)
TW (2) TWI712422B (enExample)
WO (1) WO2012170952A2 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI549691B (zh) * 2010-06-17 2016-09-21 日東電工股份有限公司 腎纖維症處置劑
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
EP3673898A1 (en) * 2011-11-04 2020-07-01 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
CA2876148C (en) 2012-06-08 2021-01-12 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
JP6076076B2 (ja) 2012-12-21 2017-02-08 日東電工株式会社 組織再生促進剤
US9365610B2 (en) 2013-11-18 2016-06-14 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for RNA delivery
AU2014348212C1 (en) * 2013-11-18 2018-11-29 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US9976142B2 (en) 2014-04-02 2018-05-22 Nitto Denko Corporation Targeting molecule and a use thereof
US10093931B2 (en) 2014-06-17 2018-10-09 Nitto Denko Corporation Apoptosis inducer
EP2966068A1 (en) * 2014-07-08 2016-01-13 Incella GmbH Synthesis and use of amino lipids
CN104174034A (zh) * 2014-08-20 2014-12-03 南京大学 肝星状细胞靶向的基因药物输送载体及其制备方法和应用
WO2016068160A1 (ja) * 2014-10-30 2016-05-06 Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ株式会社 局所投与用リポプレックスの新規製造方法及び該リポプレックスを使用する抗腫瘍剤
PL3221293T3 (pl) * 2014-11-18 2023-07-10 Arcturus Therapeutics, Inc. Jonizowalny kationowy lipid do dostarczania rna
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
AU2016281685B2 (en) * 2015-06-24 2021-08-12 Nitto Denko Corporation Ionizable compounds and compositions and uses thereof
JP7041616B2 (ja) * 2015-09-14 2022-03-24 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム リポカチオン性デンドリマーおよびその使用
CN105194689A (zh) * 2015-10-10 2015-12-30 湖南中楚博生物科技有限公司 一种基于siRNA的双偶联复合物
EP3458074B1 (en) * 2016-05-16 2024-04-17 Board of Regents of the University of Texas System COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH
CA3024129A1 (en) * 2016-05-16 2017-11-23 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
JP6833456B2 (ja) 2016-11-02 2021-02-24 日東電工株式会社 皮膚線維症処置剤
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
CN110831586B (zh) * 2017-05-23 2023-06-13 密执安大学评议会 二甲基-壬四烯基-三甲基-环己基化合物及其用途
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
CA3071968A1 (en) 2017-08-04 2019-02-07 Kyowa Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticle
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
US11298371B2 (en) 2017-10-11 2022-04-12 Nitto Denko Corporation Regulation of nucleic acid molecule expression
WO2019090359A1 (en) 2017-11-06 2019-05-09 Nitto Denko Corporation Fusogenic compounds for delivery of biologically active molecules
CN112437674A (zh) * 2018-04-11 2021-03-02 新墨西哥科技大学研究园公司 用于药物递送的脂质前药
PL3805198T3 (pl) 2018-06-08 2024-02-12 Fujifilm Corporation Związek, jego sól i cząstki lipidowe
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
JP7453145B2 (ja) * 2018-08-22 2024-03-19 日東電工株式会社 Ｈｓｐ４７の阻害物質を用いた、化学療法剤感受性の増強
GB2606038B (en) 2018-09-04 2023-05-03 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
CN112930198A (zh) 2018-09-04 2021-06-08 德克萨斯大学系统董事会 用于核酸的器官特异性递送的组合物和方法
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN110124049B (zh) * 2019-04-29 2023-09-22 大连医科大学 聚乙二醇化芬维a胺前体药物及其用途
EP3981435B1 (en) 2019-06-07 2023-08-16 FUJIFILM Corporation Lipid composition
KR102228271B1 (ko) 2019-07-16 2021-03-17 한국과학기술연구원 항암활성을 갖는 면역조절 단백질-siRNA 복합체
CN111248152A (zh) * 2020-03-17 2020-06-09 上海市中医医院 一种肝硬化腹水动物模型及其构建方法
EP4139280A4 (en) * 2020-04-23 2024-08-07 Purdue Research Foundation LINKS TO TREATMENT OF SARS
KR102361479B1 (ko) * 2020-06-18 2022-02-11 고려대학교 산학협력단 ｓｉＲＮＡ의 생성 및 기능 증진 활성을 갖는 ＣＭＴＲ１의 신규용도
IL299263A (en) * 2020-06-24 2023-02-01 Bristol Myers Squibb Co A process for the synthesis of lipids
WO2021262745A1 (en) 2020-06-24 2021-12-30 Bristol-Myers Squibb Company Process for synthesizing cationic lipids
WO2021262743A1 (en) 2020-06-24 2021-12-30 Bristol-Myers Squibb Company Process for synthesizing targeting molecules
US20230277457A1 (en) * 2020-08-06 2023-09-07 Modernatx, Inc. Methods of preparing lipid nanoparticles
WO2022034946A1 (ko) 2020-08-14 2022-02-17 한국과학기술연구원 항암활성을 갖는 면역조절 단백질-siRNA 복합체
CN114391008B (zh) * 2020-08-20 2024-05-03 苏州艾博生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
CN114306278A (zh) * 2021-12-30 2022-04-12 上海纳米技术及应用国家工程研究中心有限公司 一种EV装载CPP-siRNA纳米颗粒的制备方法及其产品和应用
CN114805113B (zh) * 2022-01-22 2023-09-15 苏州天澜生物材料科技有限公司 一种安全高效的可降解脂质纳米颗粒及其制备方法和应用
CN114522244B (zh) * 2022-01-28 2023-09-01 浙江大学医学院附属第四医院 视黄酸修饰的lytac分子及其制备方法和应用
EP4487854A1 (en) 2022-03-03 2025-01-08 Kyushu University, National University Corporation Pharmaceutical composition for treatment or prevention of fibrotic disease
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024160826A1 (en) * 2023-01-31 2024-08-08 BioNTech SE Compositions and methods
EP4480943A1 (en) * 2023-06-22 2024-12-25 Oz Biosciences New class of lipids for delivering active ingredients into cells
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
CN117185942B (zh) * 2023-07-04 2025-09-12 清华大学 一种可用于靶向肺部递送广谱中和抗体的脂质纳米颗粒及其制备方法与应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
JPS6189286A (ja) * 1984-10-08 1986-05-07 Tokuyama Soda Co Ltd 液晶組成物
JPS61136584A (ja) * 1984-12-07 1986-06-24 Tokuyama Soda Co Ltd 液晶組成物
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
JP3029354B2 (ja) * 1992-12-22 2000-04-04 三菱電機株式会社 ディジタルビデオ信号符号化装置および復号化装置
DE69433036T2 (de) 1993-09-03 2004-05-27 Isis Pharmaceuticals, Inc., Carlsbad Aminoderivatisierte nukleoside und oligonukleoside
FR2714382B1 (fr) * 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
DE69535703T2 (de) 1994-04-13 2009-02-19 The Rockefeller University AAV-vermittelte Zufuhr von DNA an Zellen des Nervensystems
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE19640092A1 (de) * 1996-09-28 1998-04-16 Beiersdorf Ag Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind
DE19641672A1 (de) * 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
KR20050042013A (ko) * 2001-10-30 2005-05-04 넥타르 테라퓨틱스 에이엘, 코포레이션 레티노산의 수용성 중합체 콘쥬게이트
AUPR894201A0 (en) 2001-11-19 2001-12-13 Women's And Children's Hospital Respiratory delivery for gene therapy and lentiviral delivery particle
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
CA2521407A1 (en) * 2003-03-31 2004-10-21 Vectramed, Inc. Polymeric drug agents for the treatment of fibrotic disorders
JP2006254877A (ja) * 2005-03-18 2006-09-28 Fukuoka Prefecture 糖脂質を含んだキャリア及びそれを用いた遺伝子導入法
EP2476756A1 (en) * 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
WO2008001505A1 (en) * 2006-06-30 2008-01-03 Hokkaido System Science Co., Ltd. Composition for nucleic-acid introduction
JP2010527914A (ja) 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
CN101970012A (zh) * 2007-09-14 2011-02-09 日东电工株式会社 药物载体
WO2009059450A1 (en) * 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
US20100028416A1 (en) * 2008-07-30 2010-02-04 Nitto Denko Corporation Drug carriers
RU2596495C2 (ru) * 2008-09-12 2016-09-10 Нитто Денко Корпорейшн Визуализирующие агенты для фиброзных заболеваний
WO2010061880A1 (ja) * 2008-11-26 2010-06-03 中外製薬株式会社 ベシクル製剤
CA2774168C (en) * 2009-09-15 2021-02-23 Ronald Erwin Boch Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
TWI658830B (zh) * 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
JP6301742B2 (ja) * 2014-06-05 2018-03-28 ヨシモトポール株式会社 鋼管ポールおよびその設置方法

Also Published As

Publication number Publication date
JP6590888B2 (ja) 2019-10-16
EP2998289A1 (en) 2016-03-23
AU2012267467B8 (en) 2017-06-15
CN107082747A (zh) 2017-08-22
KR102029654B1 (ko) 2019-10-08
CA2837101C (en) 2020-12-15
HRP20191463T1 (hr) 2019-11-15
RU2013158456A (ru) 2015-07-20
JP2014529328A (ja) 2014-11-06
SI2998289T1 (sl) 2019-11-29
EP2718261B1 (en) 2016-02-24
JP2018065804A (ja) 2018-04-26
CN103857654A (zh) 2014-06-11
KR20140033492A (ko) 2014-03-18
LT2998289T (lt) 2019-10-25
KR102038300B1 (ko) 2019-10-31
RU2017135548A3 (enExample) 2021-01-14
TW201313256A (zh) 2013-04-01
CY1123807T1 (el) 2021-10-29
AU2012267467B2 (en) 2017-06-01
CA3094645C (en) 2023-01-03
SMT201900523T1 (it) 2019-11-13
RU2769872C2 (ru) 2022-04-07
WO2012170952A4 (en) 2013-05-30
EP2998289B1 (en) 2019-08-07
KR102029657B1 (ko) 2019-10-08
EP2718261A2 (en) 2014-04-16
CY1117433T1 (el) 2017-04-26
WO2012170952A3 (en) 2013-04-11
RU2632888C2 (ru) 2017-10-11
RS59380B1 (sr) 2019-11-29
WO2012170952A2 (en) 2012-12-13
JP5873553B2 (ja) 2016-03-01
TWI569814B (zh) 2017-02-11
DK2998289T3 (da) 2019-09-16
JP2016153477A (ja) 2016-08-25
JP6232083B2 (ja) 2017-11-15
TWI712422B (zh) 2020-12-11
PL2998289T3 (pl) 2020-01-31
CN107043334A (zh) 2017-08-15
CA3094645A1 (en) 2012-12-13
WO2012170952A9 (en) 2013-02-21
HUE045821T2 (hu) 2020-01-28
KR20180134425A (ko) 2018-12-18
HRP20191463T8 (hr) 2020-02-21
KR20180134424A (ko) 2018-12-18
ES2743540T3 (es) 2020-02-19
CN107043334B (zh) 2020-06-16
AU2012267467A1 (en) 2014-01-16
TW201711706A (zh) 2017-04-01
CA2837101A1 (en) 2012-12-13
PL2718261T3 (pl) 2016-08-31
PT2998289T (pt) 2019-09-19
AU2012267467A8 (en) 2017-06-15
DK2718261T3 (en) 2016-03-29
CN103857654B (zh) 2017-03-15
RU2017135548A (ru) 2019-02-08
CN107082747B (zh) 2020-11-20
AU2017203075A1 (en) 2017-06-01
AU2017203075B2 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
ES2570184T3 (es) Compuestos para dirigir la administración de fármacos y potenciar la actividad de ARNip
CU20130082A7 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
CO6761383A2 (es) Aminas grasas, amidoaminas y sus derivados de a metátesis de aceites naturales
BR112012033350A2 (pt) "composição e métodos para modular a via de sinalização de wnt"
UY33226A (es) Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CL2012000311A1 (es) Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales.
BR112013016595A2 (pt) inibidores de neprilisina
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
UY32630A (es) Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica.
BR112015018508A2 (pt) moduladores de enzimas modificadoras de metila, suas composições e uso
BR112013031463A2 (pt) piridina-2-amidas úteis como agonistas de cb2
CO7350652A2 (es) Piridina-2-amidas útiles como agonistas de cb2
UY32631A (es) Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparación y su aplicación en terapéutica.
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
UY34251A (es) derivados de isoxazolina como compuestos insecticidas.
EA201001087A1 (ru) Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их
GT200700057A (es) Nuevos derivados de piridazina
BR112013028368A2 (pt) novos compostos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona e octahidropiridinona
UY32246A (es) Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica
MX2013012511A (es) Control y repelente para poblaciones de cimicidae.
BR112013017923A2 (pt) derivados de 2-metóxi-piridin-4-il